Xenoport (XNPT) 7.07 $XNPT Lifshitz & Miller La
Post# of 273258
Posted On: 09/02/2016 5:03:23 PM
Xenoport (XNPT) 7.07 $XNPT
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc., LinkedIn Corporation, Mines Management, Inc., Rose Rock Midstream, L.P., STAAR Surgical Company, XenoPort, Inc. and Your Community Bankshares, Inc.
PR Newswire - Mon Jun 20, 11:52AM CDT
Exterran Corporation (EXTN) Lifshitz & Miller announces investigation on behalf of Exterran investors. Specifically, on April 26, 2016, Exterran announced it will restate its consolidated and combined financial statements for 2015 and expects to delay the filing of its Form 10-Q for the quarter ended March 31, 2016.
EXTN: 14.65 (+0.31), LNKD: 192.80 (+0.07), SAAS: 13.92 (-0.02), STAA: 8.96 (+0.25), YCB: 39.11 (+0.15), RRMS: 25.21 (+0.48), MGN: 1.28 (+0.04), XNPT: 7.07 (+0.05)
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period
BusinessWire - Thu Jun 16, 5:30AM CDT
Arbor Pharmaceuticals, LLC ("Arbor"
and XenoPort, Inc. ("XenoPort" (NASDAQ:XNPT) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced tender offer by Arbor's wholly owned subsidiary, AP Acquisition Sub, Inc. ("Acquisition Sub", to purchase all issued and outstanding shares of common stock of XenoPort.
XNPT: 7.07 (+0.05)
Surging Earnings Estimates Signal Good News for Xenoport (XNPT)
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:55AM CDT
Xenoport (XNPT) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
XNPT: 7.07 (+0.05)
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc., LinkedIn Corporation, Mines Management, Inc., Rose Rock Midstream, L.P., STAAR Surgical Company, XenoPort, Inc. and Your Community Bankshares, Inc.
PR Newswire - Mon Jun 20, 11:52AM CDT
Exterran Corporation (EXTN) Lifshitz & Miller announces investigation on behalf of Exterran investors. Specifically, on April 26, 2016, Exterran announced it will restate its consolidated and combined financial statements for 2015 and expects to delay the filing of its Form 10-Q for the quarter ended March 31, 2016.
EXTN: 14.65 (+0.31), LNKD: 192.80 (+0.07), SAAS: 13.92 (-0.02), STAA: 8.96 (+0.25), YCB: 39.11 (+0.15), RRMS: 25.21 (+0.48), MGN: 1.28 (+0.04), XNPT: 7.07 (+0.05)
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period
BusinessWire - Thu Jun 16, 5:30AM CDT
Arbor Pharmaceuticals, LLC ("Arbor"
and XenoPort, Inc. ("XenoPort" (NASDAQ:XNPT) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced tender offer by Arbor's wholly owned subsidiary, AP Acquisition Sub, Inc. ("Acquisition Sub", to purchase all issued and outstanding shares of common stock of XenoPort. XNPT: 7.07 (+0.05)
Surging Earnings Estimates Signal Good News for Xenoport (XNPT)
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:55AM CDT
Xenoport (XNPT) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
XNPT: 7.07 (+0.05)
(0)
(0)Scroll down for more posts ▼